ImCheck TherapeuticsImCheck Therapeutics
ImCheck Therapeutics

ImCheck Therapeutics

ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies.

Website
2015Active47
Advertise here

About

ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of immuno-oncology drugs. Their approach targets novel immune checkpoints to modulate the tumor microenvironment and enhance anti-tumor immunity. The company's lead product candidate, IMC-001, is a first-in-class antibody targeting the TIGIT receptor.

Technology stack

detected 2026-06-17
Est. monthly stack spend~$490/mo
Emailunknown
Hosting
self_managed
Stack
jQueryTailwind CSSBootstrap
Analytics
Google Analytics 4
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does ImCheck Therapeutics do?

ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of immuno-oncology drugs. Their approach targets novel immune checkpoints to modulate the tumor microenvironment and enhance anti-tumor immunity. The company's lead product candidate, IMC-001, is a first-in-class antibody targeting the TIGIT receptor.

How much funding has ImCheck Therapeutics raised?

ImCheck Therapeutics has raised a total of $234M in funding.

Where is ImCheck Therapeutics headquartered?

ImCheck Therapeutics is headquartered in Marseille, France.

When was ImCheck Therapeutics founded?

ImCheck Therapeutics was founded in 2015.

What industry does ImCheck Therapeutics operate in?

ImCheck Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Immuno-Oncology.

How many employees does ImCheck Therapeutics have?

ImCheck Therapeutics has approximately 47 people on record.